Ovid Therapeutics to Discuss Positive Initial Data from Ongoing ENDYMION Trial Call Transcript
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Ovid Therapeutics Conference Call. (Operator Instructions) It is now my pleasure to turn the call over to Mr. [Matt David], Head of Strategy for Ovid Therapeutics. Please go ahead, sir.
Thank you, operator, and thank you, everyone for dialing in today. Earlier this morning, Ovid issued a press release providing an overview of initial data from the ENDYMION open-label extension trial of soticlestat in patients with rare epilepsies. This press release can be found on our website at www.ovidrx.com. Please note that we will have webcast slides to accompany this call. For those dialing in, it may be helpful to go to the Investor's page of our website and access the webcast player, if you haven't done so already. A PDF of the webcast slides are also available on our website.
Joining me on the call this morning are Dr. Jeremy Levin, our Chairman and Chief Executive Officer; and Dr. Amit Rakhit, our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
